Zobrazeno 1 - 10
of 50
pro vyhledávání: '"gemcitabine-refractory"'
Publikováno v:
BMC Cancer, Vol 21, Iss 1, Pp 1-9 (2021)
Abstract Background According to the NAPOLI-1 trial, nanoliposomal irinotecan (nal-IRI) plus fluorouracil/folinic acid (5-FU/LV) showed improved overall survival compared to fluorouracil alone for patients with metastatic pancreatic cancer who were p
Externí odkaz:
https://doaj.org/article/4925642ab4544182841d608bafad7bf1
Publikováno v:
World Journal of Gastrointestinal Oncology
BACKGROUND There is no standard therapy for second-line treatment of gemcitabine-refractory pancreatic cancer patients with poor performance status. A combination of chemotherapy drugs 5-fluorouracil (5-FU), leucovorin, irinotecan, and oxaliplatin (F
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3f049beeb57432a8c28dc31c4a97122e
https://doi.org/10.4251/wjgo.v11.i11.1021
https://doi.org/10.4251/wjgo.v11.i11.1021
Autor:
Huapyong Kang, Sang Hyub Lee, Dae Hwan Kang, Ho Gak Kim, Seungmin Bang, Jun Kyu Lee, Jong Jin Hyun, Kwang Hyuck Lee, Moon Jae Chung, Myung Hwan Noh
Publikováno v:
World Journal of Gastrointestinal Oncology
AIM To evaluate the efficacy and safety of modified FOLFIRINOX as a second-line treatment for gemcitabine (GEM)-refractory unresectable pancreatic cancer (PC). METHODS This study was a prospective, multicenter, one-arm, open-label, phase II trial. Pa
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::186628af89904a258b0602af05a92c23
https://doi.org/10.4251/wjgo.v10.i12.505
https://doi.org/10.4251/wjgo.v10.i12.505
Publikováno v:
BMC Cancer
BMC Cancer, Vol 21, Iss 1, Pp 1-9 (2021)
BMC Cancer, Vol 21, Iss 1, Pp 1-9 (2021)
Background According to the NAPOLI-1 trial, nanoliposomal irinotecan (nal-IRI) plus fluorouracil/folinic acid (5-FU/LV) showed improved overall survival compared to fluorouracil alone for patients with metastatic pancreatic cancer who were previously
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dc9710ae174c38c9c4c5a66e5b0f98a1
https://pubmed.ncbi.nlm.nih.gov/34732161
https://pubmed.ncbi.nlm.nih.gov/34732161
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Akira Fukutomi, Hiroyuki Isayama, Makoto Ueno, Tatsuya Ioka, J. Furuse, K. Fukuzawa, Shoji Nakamori, Haruo Iguchi, Masahiro Takeuchi, Yoshito Komatsu, Hideo Baba, Nobumasa Mizuno, Ken Shimada, Masayuki Furukawa, Masataka Ikeda, Kazuya Sugimori, Yasushi Omuro, Narikazu Boku, T. Okusaka, Ichinosuke Hyodo
Publikováno v:
Annals of Oncology
This is the first phase II trial in which adding oral leucovorin (LV) to S-1 (SL) significantly prolonged progression-free survival (PFS) when compared with S-1 monotherapy (S) in patients with gemcitabine-refractory advanced pancreatic cancer (PC).
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6abccb324bc83090aeb8676680647dcc
https://doi.org/10.1093/annonc/mdv603
https://doi.org/10.1093/annonc/mdv603
Autor:
Faysal Dane, Abdurrahman Isikdogan, Veli Berk, Ilkay Tugba Unek, Efnan Algin, Ali Inal, F. Tuba Kos, Caglayan Geredeli, Ramazan Yildiz, Dilsen Colak
Publikováno v:
Contemporary Oncology
AIM OF THE STUDY: Systemic chemotherapy for patients with pancreatic cancer has limited impact on overall survival (OS). Patients eligible for chemotherapy should be selected carefully. The aim of the study was to search for prognostic factors for su
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b0f0cd351a6c9c64f652bb27a7d1cd89
https://avesis.gazi.edu.tr/publication/details/b2831132-f172-4447-a611-f56ca741ca23/oai
https://avesis.gazi.edu.tr/publication/details/b2831132-f172-4447-a611-f56ca741ca23/oai
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Li-Tzong Chen, Andrew H. Ko, Wu Chou Su, Yeh Cg, Elizabeth Dito, Yu-Lin Lin, Shan Ys, Anna Ong, Wang Yw, Margaret A. Tempero
Publikováno v:
British Journal of Cancer
Background: PEP02, also known as MM-398, is a novel nanoliposomal irinotecan that has improved pharmacokinetics and tumour bio-distribution of the free drug. This phase 2 study evaluated PEP02 monotherapy as second-line treatment for pancreatic cance
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::92ace893331b259db48d74c659af7c70
https://pubmed.ncbi.nlm.nih.gov/23880820
https://pubmed.ncbi.nlm.nih.gov/23880820